U-51 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to GlobalData, Phase II drugs for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how U-51’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of multiple myeloma and idiopathic thrombocytopenic purpura. The drug candidate consists of autologous T cells to express third generation anti-BCMA CAR. It is administered through intravenous route. It is developed based on SMART(siRNA mediated acquired reprogramming technology) platform.
Shanghai Unicar-Therapy Bio-Medicine Technology overview
Shanghai Unicar-Therapy Bio-Medicine Technology., is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China.
For a complete picture of U-51’s drug-specific PTSR and LoA scores, buy the report here.